2023年11月29日 · Olaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.

How does olaparib work? Olaparib is a targeted drug called a PARP inhibitor. PARP is a protein that helps damaged cells to repair themselves. Olaparib stops PARP working. Some cancer cells rely on PARP to keep their DNA healthy. This includes cancer cells with …

Olaparib is also known as a PARP inhibitor. PARPs are proteins that help damaged cells repair themselves. Olaparib blocks (inhibits) how PARP proteins work. Without PARP proteins, cancer cells may become too damaged to survive, and die.

2020年6月11日 · Two recent approvals by the Food and Drug Administration (FDA) have opened a new avenue of treatment for some men with prostate cancer: an expanded role for targeted therapies. The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca).

2015年1月9日 · It is used in combination with durvalumab (another cancer medicine) after treatment with chemotherapy and durvalumab has been completed. Lynparza contains the active substance olaparib.

Olaparib works by blocking the activity of PARP enzymes, which help repair damaged DNA in cells. Cancer cells with BRCA mutations or certain other gene mutations cannot use a key DNA repair process called homologous recombination (HR) and need PARP enzymes to survive.

2019年10月29日 · In three trials, different PARP inhibitors were tested as initial treatment for women with advanced ovarian cancer. UPDATE: On May 8, 2020, the Food and Drug Administration (FDA) expanded the approval of olaparib (Lynparza) for the initial treatment of women with advanced ovarian cancer.

2024年9月24日 · PARP inhibitors are a type of targeted cancer drug. Olaparib, niraparib and rucaparib are all examples of PARP inhibitors. Find out more about them.

Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor.